-
1 Comment
Guizhou Xinbang Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 4.6% above its 200 day moving average.
From a valuation standpoint, the stock is 74.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Guizhou Xinbang Pharmaceutical Co., Ltd's total revenue sank by 4.3% to $2B since the same quarter in the previous year.
Its net income has increased by 39.2% to $50M since the same quarter in the previous year.
Finally, its free cash flow fell by 16.3% to $180M since the same quarter in the previous year.
Based on the above factors, Guizhou Xinbang Pharmaceutical Co., Ltd gets an overall score of 3/5.
| CurrencyCode | CNY |
|---|---|
| Exchange | SHE |
| ISIN | CNE100000NG5 |
| Sector | Healthcare |
| Industry | Drug Manufacturers-Specialty & Generic |
| Target Price | 7.37 |
|---|---|
| PE Ratio | 34.73 |
| Beta | 0.56 |
| Dividend Yield | 1.2% |
| Market Cap | 10B |
Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002390.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
